netarsudil

06/05/2023 - "Among the secondary glaucoma subtypes, netarsudil was found to be most effective for treating uveitic glaucoma, showing a decrease in IOP of 9.5 mm Hg after 12 months (p = 0.02). "
06/05/2023 - "Netarsudil is effective in lowering IOP in patients with certain forms of secondary glaucoma and should be considered for IOP management in those with uveitic glaucoma."
03/01/2021 - "Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG)."
10/01/2023 - "Our results suggest that although netarsudil is an alternative medication in the management of pediatric glaucoma, its efficacy may be limited in refractory pediatric glaucoma patients. "
10/01/2023 - "We performed a retrospective review of patients with refractory pediatric glaucoma who were started on netarsudil at the Wilmer Eye Institute. "

05/01/2022 - "Netarsudil-Induced Corneal Flattening in a Child with Secondary Open-Angle Glaucoma."
04/02/2021 - "Rhopressa (netarsudil) has recently been added to the arsenal of treatment for open-angle glaucoma. "
01/01/2016 - "Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma."
01/01/2018 - "In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma. "
03/01/2021 - "A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma."

07/01/2021 - "Purpose: To analyze the efficacy, safety, and accessibility of netarsudil 0.02% in patients with glaucoma (suspect, open or closed) at a safety-net academic medical center, Boston Medical Center (BMC). "
01/01/2018 - "In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma. "
03/01/2021 - "A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma."
01/01/2021 - "A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting."
01/01/2021 - "The primary objective of this phase 2 study was to evaluate ocular hypotensive efficacy and safety of three netarsudil concentrations (0.01%, 0.02%, and 0.04%) relative to its placebo over 4 weeks in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). "

11/01/2020 - "The reticular epithelial edema resolved upon discontinuation of netarsudil and best-corrected visual acuity improved to 20/50 but was limited by persistent stromal edema. "
01/01/2020 - "All patients demonstrated improvement in bullous epithelial edema after netarsudil discontinuation. "
01/01/2020 - "In all cases, the reticular bullous epithelial edema improved or resolved after discontinuation of netarsudil. "
01/01/2020 - "In 5 of 6 cases, visual acuity worsened with onset of bullous epithelial edema, and in all cases, visual acuity stabilized or improved following discontinuation of netarsudil. "
11/01/2020 - "This unique pattern of edema may present in the setting of preexisting endothelial cell dysfunction when netarsudil is used, a complication not noted in the Food and Drug Administration (FDA) trials."

07/01/2021 - "For the second eye, netarsudil was withheld 2 weeks beyond the time for corneal clearance of the first eye and then administered only if corneal edema was still present. "
01/01/2022 - "Reticular epitheliopathy is a relatively rare complication of netarsudil that has been described in patients with preexisting corneal edema. "
01/01/2022 - "Anterior segment optical coherence tomography features of netarsudil-associated reticular corneal edema."
01/01/2021 - "Four patients presenting to a busy academic clinical corneal practice with visual complaints from corneal edema secondary to endothelial cell dysfunction were treated with topical netarsudil one drop daily in the affected eye. "
01/01/2020 - "Reticular corneal edema or corneal honeycombing is an ocular examination finding that can rarely occur after initiating netarsudil (0.02%) regardless of prior corneal edema status. "